Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 10 | 2022 | 394 | 0.710 |
Why?
|
| HIV Infections | 14 | 2022 | 2207 | 0.600 |
Why?
|
| Reverse Transcriptase Inhibitors | 6 | 2015 | 55 | 0.540 |
Why?
|
| Triazoles | 3 | 2017 | 85 | 0.370 |
Why?
|
| Cyclohexanes | 2 | 2017 | 29 | 0.310 |
Why?
|
| HIV-1 | 8 | 2012 | 678 | 0.300 |
Why?
|
| HIV Fusion Inhibitors | 2 | 2017 | 4 | 0.230 |
Why?
|
| Hepatitis C | 1 | 2004 | 120 | 0.230 |
Why?
|
| Lamivudine | 4 | 2012 | 20 | 0.170 |
Why?
|
| Drug Therapy, Combination | 8 | 2015 | 217 | 0.160 |
Why?
|
| Zidovudine | 3 | 2007 | 33 | 0.150 |
Why?
|
| Stavudine | 3 | 2009 | 13 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 29 | 0.150 |
Why?
|
| Anti-Retroviral Agents | 2 | 2022 | 139 | 0.140 |
Why?
|
| RNA, Viral | 5 | 2015 | 287 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2023 | 1353 | 0.130 |
Why?
|
| Adult | 13 | 2023 | 11034 | 0.120 |
Why?
|
| Adenine | 3 | 2012 | 43 | 0.110 |
Why?
|
| Humans | 19 | 2023 | 34853 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 165 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2012 | 167 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 47 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2010 | 18 | 0.100 |
Why?
|
| Male | 14 | 2022 | 18870 | 0.100 |
Why?
|
| Middle Aged | 10 | 2017 | 9642 | 0.100 |
Why?
|
| beta-Lactam Resistance | 1 | 2009 | 4 | 0.090 |
Why?
|
| Acinetobacter | 1 | 2009 | 6 | 0.090 |
Why?
|
| Acinetobacter Infections | 1 | 2009 | 22 | 0.090 |
Why?
|
| beta-Lactamases | 1 | 2009 | 33 | 0.090 |
Why?
|
| Meningoencephalitis | 1 | 2009 | 13 | 0.090 |
Why?
|
| Mycobacterium Infections | 1 | 2009 | 16 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2015 | 185 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2017 | 269 | 0.090 |
Why?
|
| Mucormycosis | 1 | 2008 | 2 | 0.090 |
Why?
|
| Female | 12 | 2022 | 19873 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2017 | 1349 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2008 | 147 | 0.080 |
Why?
|
| Adolescent | 4 | 2023 | 5035 | 0.070 |
Why?
|
| Dioxolanes | 1 | 2006 | 2 | 0.070 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2006 | 5 | 0.070 |
Why?
|
| Purine Nucleosides | 1 | 2006 | 14 | 0.070 |
Why?
|
| Drug Resistance, Viral | 3 | 2015 | 60 | 0.070 |
Why?
|
| Dideoxynucleosides | 3 | 2012 | 11 | 0.060 |
Why?
|
| Cyclopropanes | 3 | 2012 | 39 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 964 | 0.060 |
Why?
|
| Alkynes | 3 | 2012 | 49 | 0.060 |
Why?
|
| Benzoxazines | 3 | 2012 | 46 | 0.060 |
Why?
|
| Homosexuality, Male | 2 | 2022 | 438 | 0.060 |
Why?
|
| Biopsy | 1 | 2004 | 151 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2006 | 298 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 30 | 0.060 |
Why?
|
| Time Factors | 4 | 2011 | 1681 | 0.060 |
Why?
|
| HIV Protease Inhibitors | 1 | 2002 | 22 | 0.060 |
Why?
|
| Aged | 5 | 2017 | 6448 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2023 | 1961 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 214 | 0.050 |
Why?
|
| Neoplasms | 1 | 2011 | 1033 | 0.050 |
Why?
|
| Deoxycytidine | 2 | 2012 | 21 | 0.050 |
Why?
|
| Young Adult | 3 | 2017 | 4012 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2022 | 165 | 0.050 |
Why?
|
| Incidence | 2 | 2011 | 882 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 2017 | 26 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2009 | 203 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2022 | 587 | 0.040 |
Why?
|
| HIV | 1 | 2015 | 97 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2006 | 65 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 984 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 2333 | 0.030 |
Why?
|
| Indinavir | 2 | 2003 | 2 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 145 | 0.030 |
Why?
|
| Nelfinavir | 2 | 2003 | 3 | 0.030 |
Why?
|
| Ritonavir | 1 | 2012 | 14 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2012 | 89 | 0.030 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2012 | 31 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2012 | 97 | 0.030 |
Why?
|
| Pyridines | 1 | 2012 | 113 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2010 | 51 | 0.020 |
Why?
|
| Bone Density | 1 | 2010 | 76 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 38 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2009 | 9 | 0.020 |
Why?
|
| Granuloma | 1 | 2009 | 23 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 454 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 212 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2009 | 231 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 1007 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 727 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 429 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2009 | 1352 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 255 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 224 | 0.020 |
Why?
|
| Kinetics | 1 | 2006 | 650 | 0.020 |
Why?
|
| Viral Load | 1 | 2006 | 300 | 0.020 |
Why?
|
| Smoking | 1 | 2011 | 903 | 0.020 |
Why?
|
| Oxazines | 1 | 2003 | 23 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 406 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2006 | 628 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 3414 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 1289 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 641 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 650 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2002 | 202 | 0.010 |
Why?
|